New research indicates that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Published data in a major medical journal shows that while overweight individuals frequently drop a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such drugs need to be aware of the danger of fast rebound weight gain when the medication concludes," warns researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment weight within about 18 months.
Weighing Approaches
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who shed pounds through diet and exercise typically experience a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors suggest the way of the injections explains the accelerated regain.
These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts contend that, given the likelihood of relapse, the therapy is often ongoing.
This view is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the jabs report a powerful resurgence of appetite.
"I experienced something that goes on and you become extremely hungry," described a patient.
This challenge is exacerbated if patients have not developed permanent lifestyle or habit modifications during treatment.
Growing Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while the jabs are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on combined lifestyle support.
